Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2007-06-26
2007-06-26
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
active
10488279
ABSTRACT:
A method is provided for reducing hypertension and/or heart failure in a mammal. Preferably, the method is used to treat or prevent tissue damage to a human heart. The method includes administering an effective amount of a Jak2 inhibitor, preferably a tyrphostin, such as AG490.
REFERENCES:
patent: 5573772 (1996-11-01), Downey et al.
patent: 6255296 (2001-07-01), Daniels
patent: 6433018 (2002-08-01), Siddiqui et al.
patent: 2002/0028817 (2002-03-01), Levitzki et al.
patent: 98/06391 (1998-02-01), None
Zarain-Herzberg, et al., Am. J. Cardiology, 1999;83:31H-37H.
Alexander Levitzki, “Tyrphostins—Potential Antiproliferative Agents and Novel Molecular Tools,”Biochemical Pharmacology(1990) 40/5: 913-918.
Shinji Negoro, Keita Kunisada, Erioh Tone, Masanobu Funamoto, Hidemasa Oh, Tadamitsu Kishimoto, Keiko Yamauchi-Takihara, “Activation of JAK/STAT pathway transduces cytoprotective signal in rat acute myocardial infarction,”Cardiovascular Research(2000) 47: 797-805.
Alexander Levitzki and Aviv Gazit, “Tyrosine Kinase Inhibition: An Approach to Drug Development,”Science(1995) 267: 1782-1788.
Eduardo Mascareno, Manya Dhar, and M.A.Q. Siddiqui, “Signal transduction and activator of transcription (STAT) protein-dependent activation of angiotensinogen promoter: A cellular signal for hypertrophy in cardiac muscle,”Proc. Natl. Acad. Sci. USA(1998) 95: 5590-5594.
Naftaly Meydan, Tom Grunberger, Harjit Dadi, Michal Shahar, Enrico Arpaia, Zvi Lapidot, J. Steven Leeder, Melvin Freedman, Amos Cohen, Aviv Gazit, Alexander Levitzki and Chaim M. Roifman, “Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor,”Nature(1996) 379: 645-648.
Alexander Levitzki, “Protein Tyrosine Kinase Inhibitors as Novel Therapeutic Agents,”Pharmacol. Ther.(1999) 82/2-3: 231-239.
Eduardo Mascareno and M.A.Q. Siddiqui, “The role of Jak/STAT signaling in heart tissue renin-angiotensin system,”Molecular and Cellular Biochemistry(2000) 212: 171-175.
Domenica Altavilla, Francesco Squadrito, Giuseppe M. Campo, Antonino Saitta, Giovanni Squadrito, Cristina Quartarone, Barbara Deodato, Mariarita Arlotta, Marcella Ferlito, Letteria Minutoli, Michelangelo Tringali, Giuseppe Urna, Aurora Sardella, Achille P. Caputi, “The reduction of myocardial damage and leukocyte polymorphonuclear accumulation following coronary artery occlusion by the tyrosine kinase inhibitor tyrphostin AG 556,”Life Sciences(2000) 67: 2615-2629.
Stephanie W. Watts, Jennifer A. Florian and Kimberly M. Monroe, “Dissociation of Angiotensin II-Stimulated Activation of Mitogen-Activated Protein Kinase Kinase from Vascular Contraction,”The Journal of Pharmacology and Experimental Therapeutics(1998) 286/3: 1431-1438.
Shao-Ling Zhang, Catherine To, Xing Chen, Janos G. Filep, Shiow-Shih Tang, Julie R. Ingelfiner, Serge Carrière, John S.D. Chan, “Effect of Renin-Angiotensin System Blockade on the Expression of the Angiotensinogen Gene and Induction of Hypertrophy in Rat Kidney Proximal Tubular Cells,”Experimental Nephrology(2001) 9: 109-117.
Cindy Ruwhof, Arnoud van der Laarse, “Mechanical stress-induced cardiac hypertrophy: mechanisms and signal transduction pathways,”Cardiovascular Research(2000) 47: 23-37.
Michael M. Givertz, MD, “Manipulation of the Renin-Angiotensin System,”Circulation(2001) 104: e14-e18.
Diane H. Boschelli, “Small molecule inhibitors of receptor tyrosine kinases,” www.prous.com/journals/dof/sample/html/df240515/df240515.html.Date of publication unknown.
Eduardo Mascareno, PhD; Mohammed El-Shafei, MD; Nilanjana Maulik, PhD; M.Sato, MD; Yueling Guo; Dipak Das, PhD; M.A.Q. Siddiqui, Phd, “JAK/STAT Signaling Is Associated With Cardiac Dysfunction During Ischemia and Reperfusion,”Circulation(2001) 104:1-5.
DL Beckles, E. Mascareno, and MAQ Siddiqui, “Attenuation of Cardiac Hypertrophy in vivo by Interference with Activation of the Jak/Stat Pathway,” presented at theXVII World Congress of the International Society for Heart Research, Winnipeg, Manitoba, Canada (Jul. 6-11, 2001).
Beckles Daniel Lincoln
Mascareno Eduardo
Siddiqui Mohammed A. Q.
Henley III Raymond J.
Hoffmann & Baron , LLP
The Research Foundation of State University of New York
LandOfFree
Method for reducing hypertension and heart failure does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for reducing hypertension and heart failure, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for reducing hypertension and heart failure will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3839071